12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Replagal agalsidase alfa regulatory update

Shire withdrew a BLA for Replagal agalsidase alfa to treat Fabry's disease and said it does not intend to resubmit the application. Shire said that based on recent interactions with FDA, it believes the agency will require additional controlled studies before approving the drug. The application was under Priority Review with a May 17 PDUFA date. As...

Read the full 263 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >